Overly protective caregivers and an excessive focus on minor health concerns have also been implicated as potential causes of hypochondriasis.In the media and on the Internet, articles, TV shows, and advertisements regarding serious illnesses such as cancer and multiple sclerosis often portray these diseases as being random, obscure, and somewhat inevitable. In the short term, inaccurate portrayal of risk and the identification of non-specific symptoms as signs of serious illness may contribute to exacerbating fear of illness. Major disease outbreaks or predicted pandemics can have similar effects. Anecdotal evidence suggests that some individuals become hypochondriac after experiencing major medical diagnosis or death of a family member or friend. Similarly, when approaching the age of a parents premature death from disease, many otherwise healthy, happy individuals fall prey to hypochondria. These individuals believe they have the same disease that caused their parents death, sometimes causing panic attacks with corresponding symptoms. Diagnosis
The ICD-10 defines hypochondriasis as follows:

A. Either one of the following:
A persistent belief, of at least six months duration, of the presence of a minimum of two serious physical diseases (of which at least one must be specifically named by the patient). A persistent preoccupation with a presumed deformity or disfigurement (body dysmorphic disorder).B. Preoccupation with the belief and the symptoms causes persistent distress or interference with personal functioning in daily living and leads the patient to seek medical treatment or investigations (or equivalent help from local healers).C.
Sarecycline is a narrow-spectrum tetracycline-derived antibiotic. It is specifically designed for the treatment of acne, and was approved by the FDA in October 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Two randomized and well-controlled clinical trials reported efficacy data on both facial and truncal acne (back and chest). Efficacy was assessed in a total of 2002 subjects 9 years of age and older. Unlike other tetracycline-class antibiotics, sarecycline has a long C7 moiety that extends into and directly interact with the bacterial messenger RNA (mRNA). The spectrum of activity is limited to clinically relevant Gram-positive bacteria, mainly Cutibacterium acnes, with little or no activity against Gram-negative bacterial microflora commonly found in the human gastrointestinal tract. Sarecycline has not been tested in spirochetes. References
External links
"Sarecycline". Drug Information Portal. U.S. National Library of Medicine.